Date: 2011-06-07
Type of information: Commercialisation agreement
Compound: Graspa® (asparaginase encapsulated into red blood cells)
Company: Erytech Pharma (France) Teva Pharmaceuticals (Israel)
Therapeutic area: Cancer - Oncology
Type agreement: registration
marketing
distribution
commercialisation
Action mechanism:
Disease:
Details: ERYTECH Pharma has signed an exclusive long term agreement with Teva for the registration, marketing, distribution and sale of Graspa®, the company’s lead product, in Israel. Teva leading position, long history in oncology and specialty segment will provide a solid platform for Graspa® and made them an ideal partner for product market introduction in Israel. ERYtech anticipates that first sales could be generated in less than 15 months. Under the terms of the agreement, Teva will submit the drug for approval in Israel, market and distribute it in the territory for a long term period. Clinical trials are underway in pancreatic cancer and acute lymphoblastic leukemia,
Financial terms: Teva will pay milestone payments in addition to sharing profit on the basis of purchase price agreed with Teva.
Latest news:
